Calliditas Therapeutics

Focus: Calliditas is a Swedish biotech company focused on immunology with a commercial-stage small molecule portfolio anchored by TARPEYO (budesonide), approved for multiple respiratory and GI indications.

Immunology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Calliditas Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Calliditas Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TARPEYO

Asthma, COPD, Eosinophilic Esophagitis

$16M Part D

Peak16.7yr

Only approved revenue-generating product; budesonide LOE in 2043 provides extended exclusivity window but near-term success depends on market adoption and label expansion.

Help build intelligence for Calliditas Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Xepol

Post Polio Syndrome, PPS

N/A

Clinical Trials (1)

NCT00160082Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS)

N/A

GKT137831

Phase 1

Clinical Trials (1)

NCT03740217Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

Phase 1

Setanaxib

Phase 1

Clinical Trials (1)

NCT04327089Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects

Phase 1

Setanaxib

Alport Syndrome

Phase 1/2

Clinical Trials (1)

NCT06274489A Study to Evaluate Setanaxib in Patients With Alport Syndrome

Phase 1/2

Setanaxib

Primary Biliary Cholangitis

Phase 2

Clinical Trials (1)

NCT05014672A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

Phase 2

GKT137831

Primary Biliary Cirrhosis

Phase 2

Clinical Trials (1)

NCT03226067Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.

Phase 2

GKT137831

Type 2 Diabetes Mellitus With Diabetic Nephropathy

Phase 2

Clinical Trials (1)

NCT02010242Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria

Phase 2

Setanaxib

Squamous Cell Carcinoma of Head and Neck

Phase 2

Clinical Trials (1)

NCT05323656A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Phase 2

NEFECON

Primary IgA Nephropathy

Phase 2

Clinical Trials (1)

NCT01738035The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease

Phase 2

Budesonide

IGA Nephropathy

Phase 2

Clinical Trials (1)

NCT00767221Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study